These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 37165196)

  • 21. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
    Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
    Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
    Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
    Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
    Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
    Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines.
    Kang Y; Zhang W; Yu Q; Gao L; Quan J; Gu F; Wu Y; Tian Y; Wu Z; Shao S; Zhou H; Duan S; Zhou Y; Zhang L; Gao X; Tian H; Yao W
    Cancer Immunol Immunother; 2023 Aug; 72(8):2741-2755. PubMed ID: 37119260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.
    Zhang X; Xu Z; Dai X; Zhang X; Wang X
    Front Immunol; 2023; 14():1104860. PubMed ID: 36761724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.
    Peng S; Chen S; Hu W; Mei J; Zeng X; Su T; Wang W; Chen Z; Xiao H; Zhou Q; Li B; Xie Y; Hu H; He M; Han Y; Tang L; Ma Y; Li X; Zhou X; Dai Z; Liu Z; Tan J; Xu L; Li S; Shen S; Li D; Lai J; Peng B; Peng Z; Kuang M
    Cancer Immunol Res; 2022 Jun; 10(6):728-744. PubMed ID: 35476700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.
    Bailey P; Chang DK; Forget MA; Lucas FA; Alvarez HA; Haymaker C; Chattopadhyay C; Kim SH; Ekmekcioglu S; Grimm EA; Biankin AV; Hwu P; Maitra A; Roszik J
    Sci Rep; 2016 Oct; 6():35848. PubMed ID: 27762323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.
    Yang X; Fan J; Wu Y; Ma Z; Huang J; Zhang Y; Zhou Z; Mo F; Liu X; Yuan H; Xu Y; Pan L; Chen S
    Nanomedicine; 2021 Oct; 37():102443. PubMed ID: 34303839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Fit-for-Purpose Method to Measure Circulating Levels of the mRNA Component of a Liposomal-Formulated Individualized Neoantigen-Specific Therapy for Cancer.
    Guelman S; Zhou Y; Brady A; Peng K
    AAPS J; 2022 May; 24(3):64. PubMed ID: 35501406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
    Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
    J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A liposomal RNA vaccine inducing neoantigen-specific CD4
    Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
    Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
    Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer.
    Ouyang X; Liu Y; Zhou Y; Guo J; Wei TT; Liu C; Lee B; Chen B; Zhang A; Casey KM; Wang L; Kooreman NG; Habtezion A; Engleman EG; Wu JC
    Stem Cell Reports; 2021 Jun; 16(6):1468-1477. PubMed ID: 33961792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.